All patients
Age < 65y (younger) Age > 65y cancer location (gastric) cancer location (gastro-esophageal) ECOG 0 ECOG 1 Gender, female Gender, male previous gastrectomy previous gastrectomy NO
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mGC or mGEJC - 1st line (L1), pembrolizumab plus SoC vs. Standard of Care (SoC), meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.85 [0.70; 1.03]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 0.85 [0.62; 1.17]
0.85 [0.72 ; 1.00 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 2 0% 696 low not evaluable progression or deaths (PFS)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.84 [0.70; 1.01]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 0.73 [0.53; 1.00]
0.81 [0.69 ; 0.95 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 2 0% 696 low not evaluable objective responses (ORR)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.60 [1.12; 2.28]
KEYNOTE-062 (PC vs C ; CPS>10), 2020 1.82 [1.02; 3.26]
1.66 [1.22 ; 2.24 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020, KEYNOTE-062 (PC vs C ; CPS>10), 2020 2 0% 696 low not evaluable AE (any grade)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.68 [0.19; 2.43]
0.68 [0.19 ; 2.43 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable AE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.16 [0.79; 1.71]
1.16 [0.79 ; 1.71 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable AE leading to death (grade 5)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.64 [0.39; 6.94]
1.64 [0.39 ; 6.94 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.73 [1.13; 2.66]
1.73 [1.13 ; 2.66 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable TRAE (any grade)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.40 [0.70; 2.80]
1.40 [0.70 ; 2.80 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.81 [0.48; 1.37]
0.81 [0.48 ; 1.37 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Asthenia TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.87 [0.35; 2.19]
0.87 [0.35 ; 2.19 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.49 [0.02; 14.58]
0.49 [0.02 ; 14.58 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Constipation TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.61 [0.28; 1.34]
0.61 [0.28 ; 1.34 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.83 [0.38; 1.83]
0.83 [0.38 ; 1.83 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Dizziness TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.06; 15.69]
0.98 [0.06 ; 15.69 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Dry skin TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Fatigue TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.35 [0.66; 2.76]
1.35 [0.66 ; 2.76 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.07; 58.57]
1.96 [0.07 ; 58.57 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 5.98 [0.71; 50.01]
5.98 [0.71 ; 50.01 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.70 [0.32; 1.56]
0.70 [0.32 ; 1.56 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Nausea TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.03 [0.53; 2.02]
1.03 [0.53 ; 2.02 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.87 [0.58; 1.30]
0.87 [0.58 ; 1.30 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.49 [0.60; 3.70]
1.49 [0.60 ; 3.70 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.97 [0.36; 10.84]
1.97 [0.36 ; 10.84 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Peripheral sensory neuropathy TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 5.91 [0.29; 118.71]
5.91 [0.29 ; 118.71 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Pruritus TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Rash TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.07; 58.57]
1.96 [0.07 ; 58.57 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.20 [0.49; 2.95]
1.20 [0.49 ; 2.95 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.14 [0.38; 3.45]
1.14 [0.38 ; 3.45 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Vomiting TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 0.83 [0.38; 1.83]
0.83 [0.38 ; 1.83 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable Weight decreased TRAE (grade 3-4)detailed results KEYNOTE-062 (PC vs C ; CPS>1), 2020 1.96 [0.18; 21.75]
1.96 [0.18 ; 21.75 ] KEYNOTE-062 (PC vs C ; CPS>1), 2020 1 0% 494 NA not evaluable 0.2 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 00:54 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 122,271,262,260,219,184
- treatments: 873